Compare JEF & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | ALGN |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.2B |
| IPO Year | N/A | N/A |
| Metric | JEF | ALGN |
|---|---|---|
| Price | $59.16 | $157.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $71.00 | ★ $190.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 01-07-2026 | 10-29-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 25.06 | N/A |
| EPS | 2.92 | ★ 5.16 |
| Revenue | ★ $7,231,501,000.00 | $3,982,622,000.00 |
| Revenue This Year | $5.85 | $2.58 |
| Revenue Next Year | $9.97 | $3.41 |
| P/E Ratio | ★ $20.42 | $30.45 |
| Revenue Growth | ★ 15.68 | 0.56 |
| 52 Week Low | $39.28 | $122.00 |
| 52 Week High | $82.68 | $246.19 |
| Indicator | JEF | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 73.38 |
| Support Level | $55.98 | $144.00 |
| Resistance Level | $58.25 | $152.99 |
| Average True Range (ATR) | 2.07 | 4.97 |
| MACD | 0.54 | 1.74 |
| Stochastic Oscillator | 89.10 | 92.40 |
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.